Published in Health Business Week, December 29th, 2006
Currently Synvisc is delivered through three intra-articular administrations given at one-week intervals. Genzyme undertook the current trial in an attempt to reduce treatments and the overall cost of therapy.
The prospective double-blind placebo-controlled study involved 253 patients at 21 sites in Europe. Patients were randomized to receive one...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.